Marimed ( (MRMD) ) has released its Q3 earnings. Here is a breakdown of the information Marimed presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
MariMed Inc. is a prominent multi-state cannabis operator renowned for its cultivation, production, and retail facilities, offering a diverse portfolio of award-winning cannabis brands. In its third-quarter earnings report for 2025, MariMed highlighted sequential growth in revenue, adjusted EBITDA, and operating cash flow, despite facing increased competition. The company reported a slight increase in revenue to $40.8 million compared to the same quarter last year, although it faced a net loss of $2.9 million. Key strategic moves included expanding its brand distribution to new states such as Maine, Pennsylvania, and New York, and launching adult-use sales in Delaware. The company also exited the Missouri market and plans to introduce hemp-derived THC products in Rhode Island by early 2026. Looking ahead, MariMed remains focused on expanding its brand presence in high-growth states and enhancing profitability through operational efficiencies.